

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6681)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES AND APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Change of Independent Non-Executive Director

The board (the “**Board**”) of directors (the “**Directors**”) of BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Li Yuezhong (“**Mr. Li**”) has tendered his resignation, with effect from November 18, 2025, from his office as an independent non-executive Director due to his other work commitments and personal time arrangements.

Mr. Li has confirmed that there is no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that, with effect from November 18, 2025, Mr. Tu Lei (涂雷) (“**Mr. Tu**”) has been appointed as an independent non-executive Director.

Biographical details of Mr. Tu are set out as follows:

Mr. Tu Lei (涂雷), aged 44, has ample experience in corporate finance and corporate management.

Mr. Tu worked at various branches of Standard Chartered Bank under Standard Chartered PLC, a company listed on the London Stock Exchange (stock code: STAN) and the Stock Exchange (stock code: 2888), from April 2005 to September 2016, where he successively held roles including associate, associate director, director and executive director. From September 2016 to July 2023, he continued his career at different branches of Credit Suisse Group AG, where he successively worked as managing director, head of structuring of Greater China of APAC financing group and head of APAC financing group of North Asia at Credit Suisse (Hong Kong) Limited; chief executive officer and member of the board at Credit Suisse Securities (China) Limited; and managing director and co-head and head of APAC financing group at Credit Suisse (Hong Kong) Limited. From July 2023 to September 2025, Mr. Tu served as managing director and head of APAC corporate book of global lending unit at UBS Group.

Mr. Tu obtained his bachelor's degrees in computer science and economics from Truman State University in the United States in December 2004.

Mr. Tu has signed a letter of appointment with the Company, pursuant to which he will hold office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting, and thereafter will be subject to retirement by rotation and re-election at the Company's annual general meeting in accordance with the articles of association of the Company. Upon re-election, his term of office will be for a period of three years from the date of such annual general meeting. The appointment of Mr. Tu as an independent non-executive Director may be terminated by three (3) months' notice in writing served by either party on the other. Mr. Tu is entitled to a director's fee of HK\$300,000 per annum for his service as an independent non-executive Director, which was determined by the Board with reference to the recommendation from the remuneration committee of the Board (the "**Remuneration Committee**") and having regard to his duties and responsibilities, performance, qualification, experience, as well as prevailing market conditions and the remuneration policy of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Tu (i) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) does not hold any other position in the Group; (iii) did not hold any directorship in public companies the securities of which were listed on any securities market in Hong Kong or overseas in the three years immediately prior to the date of this announcement; and (iv) does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Tu has also confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the date of this announcement; (iii) that there are no other factors that may affect his independence at the time of his appointment; and (iv) that there is no other information in relation to his appointment that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules or any other matter in relation to his appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warmest welcome to Mr. Tu in joining the Board.

Change in Composition of Board Committees

The Board further announces that the following changes in composition of the Board committees, have taken effect on November 18, 2025:

1. Mr. Li ceased to be the chairman of the Remuneration Committee, a member of the audit committee of the Board (the “**Audit Committee**”) and a member of the nomination committee of the Board (the “**Nomination Committee**”);
2. Mr. Tu has been appointed as the chairman of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee; and
3. Ms. Li Mingqiu (李明秋) and Mr. Lam Yiu Por (林曉波) have been appointed as members of the Nomination Committee.

Following the above changes, the Audit Committee comprises Mr. Lam Yiu Por (林曉波) (chairman), Mr. Tu Lei (涂雷) and Dr. Duan Tao (段濤). The Remuneration Committee comprises Mr. Tu Lei (涂雷) (chairman), Mr. Lam Yiu Por (林曉波) and Dr. Duan Tao (段濤). The Nomination Committee comprises Mr. Tan Zheng (譚錚) (chairman), Mr. Tu Lei (涂雷), Dr. Duan Tao (段濤), Ms. Li Mingqiu (李明秋) and Mr. Lam Yiu Por (林曉波).

Appointment of Chief Executive Officer

The Board further announces that, with immediate effect, Mr. Cai Longjun (蔡龍軍) (“**Mr. Cai**”), chief technology officer and chief operating officer of the Group, was appointed as chief executive officer of the Company.

Biographical details of Mr. Cai are set out as follows:

Mr. Cai Longjun (蔡龍軍), aged 42, was appointed as our chief technology officer and chief operating officer in January 2022 and was appointed as chief executive officer on November 18, 2025. He currently serves as a senior engineer of Beijing Zhijingling Technology Co., Ltd. (北京智精靈科技有限公司), a subsidiary of the Company. Mr. Cai is responsible for R&D of product and technology, overall operations, policies and business of the Group.

Mr. Cai has served managerial positions at our subsidiaries, including those as set out below:

Name of the Company	Position	Period of Service
Beijing Zhijingling Technology Co., Ltd. (北京智精靈科技有限公司)	Director, manager and financial controller	June 2025
Zhejiang BrainAurora Medical Technology Co., Ltd. (浙江腦動極光醫療科技有限公司)	Director, manager and financial controller	June 2025
Zhejiang Zhiling Ruidong Medical Technology Co., Ltd. (浙江智靈睿動醫療科技有限公司)	Director, manager and financial controller	June 2025
Beijing Hongze Technology Development Co., Ltd. (北京宏澤科技發展有限公司)	Director and manager	June 2025

Name of the Company	Position	Period of Service
Changsha Zhijingling Education Technology Co., Ltd. (長沙智精靈教育科技有限公司)	Executive director and manager	June 2025
Beijing Yihui Technology Co. Ltd. (北京益慧科技有限公司)	Director and manager	June 2025
Sichuan BrainAu Medical Technology Co., Ltd. (四川腦動極光醫療科技有限公司)	Director and general manager	June 2025
BrainAurora Medical Technology (Hebei) Co., Ltd. (腦動極光(河北)醫療科技有限公司)	Director and manager	June 2025
Luzhou BrainAu Medical Technology Co., Ltd. (瀘州腦動極光醫療科技有限公司)	Director and manager	June 2025
Jiangsu BrainAurora Medical Technology Co., Ltd. (江蘇腦動極光醫療科技有限公司)	Director	June 2025
BrainAurora Limited	Director	June 2025
BrainAurora (HK) Medical Technology Limited	Director	June 2025

Mr. Cai has over 15 years of experience in computer science. Mr. Cai has served as the software developer in International Commercial Machine (China) Investment Co., Ltd. (國際商業機器(中國)投資有限公司), the subsidiary of International Business Machines Corporation, a company listed on Nasdaq (stock ticker: IBM) from July 2008 to October 2012. From September 2012 to October 2016, he served as a scientist in Beijing Qiyi Century Technology Co., Ltd. (北京奇藝世紀科技有限公司), the subsidiary of iQIYI, Inc., a company listed on Nasdaq (stock ticker: IQ). From February 2017 to January 2022, he served as a senior algorithm expert in the branch of Youku Network Technology (Beijing) Co., Ltd. (優酷網絡技術(北京)有限公司), the subsidiary of Alibaba Group Holding Limited, a company listed on the Stock Exchange (stock code: 09988.HK) and the Nasdaq (stock ticker: BABA). The above various managerial and technical roles which Mr. Cai has assumed in such major international internet companies provide him the skills, experience and expertise in the files of big data, algorithms, internet technologies, and project development. These are transferable and necessary to him discharging the roles as our chief technology officer and chief operating officer which, among others, require him to have acquired deep insights and necessary technological know-hows in the digital therapeutics (“DTx”) industry that heavily involves the above-mentioned technologies as well.

Mr. Cai obtained a bachelor’s degree in Beijing Jiaotong University (北京交通大學) in China in July 2006 and also a master’s degree in Beijing Jiaotong University in June 2008.

Mr. Cai has signed a service contract with the Company on November 18, 2025, and his term of office will be for a period of three years from November 18, 2025. The service contract may be terminated by not less than 30 days’ notice in writing served by either Mr. Cai or the Company. Pursuant to the service contract entered into with the Company, Mr. Cai is entitled to a service fee of RMB1,132,800 per annum for his service as the chief executive officer, which was determined by the Board with reference to the recommendation from the Remuneration Committee and having regard to his duties and responsibilities, performance, qualification, experience, as well as prevailing market conditions and the remuneration policy of the Company.

As at the date of this announcement, Mr. Cai is interested in 12,631,000 underlying shares in respect of the outstanding share awards granted by the Company under the Pre-IPO Share Award Scheme adopted by the Company effective on July 30, 2023.

Save as disclosed above, as at the date of this announcement, Mr. Cai (i) does not have any relationship with any Directors, senior management, substantial shareholder or controlling shareholders of the Company; (ii) does not hold any other position in the Group; (iii) did not hold any directorship in public companies the securities of which were listed on any securities market in Hong Kong or overseas in the three years immediately prior to the date of this announcement; (iv) does not have any other major appointments and professional qualifications; (v) does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (vi) does not have other information relating to his appointment that is required to be disclosed pursuant to any provisions under Rule 13.51(2) of the Listing Rules, and any other matter relating to his appointment that needs to be brought to the attention of shareholders of the Company.

The Board would like to extend its warmest welcome to Mr. Cai on his appointment.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, November 18, 2025

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive Director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive Directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive Directors.